The D.C. Diagnosis newsletter discusses Trump’s vague stance on the abortion pill mifepristone, Democrats preparing to reveal Medicare-negotiated drug prices, FDA rejecting MDMA for PTSD treatment, regulators considering new alcohol labels, and a new advocacy group challenging food corporations. The newsletter also highlights a complaint in Texas regarding delayed care due to abortion laws endangering fertility, FDA approving an EpiPen alternative, and Senator Schumer’s plan to block CDC budget cuts. Overall, the newsletter covers various political and health-related topics, providing insights and updates on current events in the industry.
Source link
Trump, Vance, and Harris on mifepristone
